Columbia Wanger Sold 2 Stakes in September

Divested holdings were in diagnostics and research industry

Author's Avatar
David Goodloe
Oct 07, 2016
Article's Main Image

Columbia Wanger (Trades, Portfolio) sold two stakes from its portfolio on Sept. 30.

The guru sold its 2,611,401-share stake in Cepheid Inc. (

CPHD, Financial), a California-based scientific and technical instrument company, for $52.69 per share. The divestiture had a -0.93% impact on the portfolio.

Cepheid has introduced a CE marked bladder cancer test in Germany that will be available across Europe in the near future. The test is said to produce accurate noninvasive results in less than two hours.

PRIMECAP Management (Trades, Portfolio), with a stake of 2,422,300 shares, is now Cepheids leading shareholder among the gurus. The stake is 3.32% of Cepheids outstanding shares and 0.08% of PRIMECAPs total assets. Other shareholders among the gurus are Manning & Napier Advisors Inc., Mario Gabelli (Trades, Portfolio), Jim Simons (Trades, Portfolio), Steven Cohen (Trades, Portfolio), Paul Tudor Jones (Trades, Portfolio) and Ron Baron (Trades, Portfolio).

Cepheid has a forward price-earnings (P/E) ratio of 111.11, a price-book (P/B) ratio of 10.22 and a price-sales (P/S) ratio of 6.76. GuruFocus gives Cepheid a Financial Strength rating of 6/10 and a Profitability and Growth rating of 6/10 with return on equity (ROE) of -13.27% that is lower than 53% of the companies in the Global Diagnostics & Research industry and return on assets (ROA) of -6.00% that is higher than 51% of the companies in that industry.

890447093.png

Cepheid sold for $52.75 per share at market close Friday. The DCF Calculator gives Cepheid a fair value of $-7.28.

Columbia Wanger (Trades, Portfolio) sold its 1,777,282-share stake in Fluidigm Corp. (FLDM, Financial), a biological research equipment company based in California, for $8.01 per share. The divestiture had a -0.19% impact on the portfolio.

PRIMECAP Management (Trades, Portfolio) is Fluidigms leading shareholder among the gurus with a stake of 4,250,732 shares. The stake is 14.64% of Fluidigms outstanding shares and 0.04% of the gurus total assets. Jim Simons (Trades, Portfolio) also owns shares in the company.

Fluidigm has a P/B of 2.71 and a P/S of 1.88. GuruFocus gives Fluidigm a Financial Strength rating of 4/10 and a Profitability and Growth rating of 1/10 with ROE of -54.59% that is lower than 71% of the companies in the Global Diagnostics & Research industry and ROA of -16.52% that is lower than 55% of the companies in that industry.

569639895.png

Fluidigm sold for $7.75 per share Friday. The DCF Calculator gives Fluidigm a fair value of $-22.47.

Disclosure: I do not own any stocks mentioned in this article.

Start a free seven-day trial of Premium Membership to GuruFocus.

Also check out:
Rating:
0 / 5 (0 votes)
Author's Avatar
I'm a journalist by training. I grew up in Arkansas and earned my B.A. at the University of Arkansas. I earned my master's degree at the University of North Texas. My background includes stints at newspapers in Arkansas and Texas and teaching news writing and news editing to students at the University of Oklahoma and Richland College here in Dallas. I'm a writer/editor at GuruFocus.